Results 41 to 50 of about 20,263 (262)
A case report on varenicline induced delirium in an alcohol and nicotine dependent patient
Indian Journal of Psychological Medicine, 2015 Varenicline is a smoking cessation agent. Varenicline acts as a partial agonist of α4β2 neuronal nicotinic acetylcholine receptor and prevents nicotine binding to the same.
A Lakshmi Narayan +5 more
doaj +1 more source
Varenicline and Risk of Self-Harm: A Nested Case-Control Study. [PDF]
PLoS ONE, 2016 BACKGROUND:Smoking remains a serious public health concern. Pharmacotherapy for smoking cessation, including bupropion and varenicline, are proven means to increase quit rates.
Mina Tadrous +6 more
doaj +1 more source
Nicotine-replacement therapy: A proven treatment for smoking cessation [PDF]
, 2010 Smoking is a major cause of cardiovascular diseases, respiratory diseases and cancer. Despite the high prevalence of smokers worldwide, smokers are often neglected and not offered effective assistance with quitting their habits. In order to overcome this
Robson, Noorzurani
core +1 more source
Varenicline Effects on Smoking, Cognition, and Psychiatric Symptoms in Schizophrenia: A Double-Blind Randomized Trial. [PDF]
PLoS ONE, 2016 UNLABELLED:Schizophrenic patients have a high rate of smoking and cognitive deficits which may be related to a decreased number or responsiveness of nicotinic receptors in their brains.
Robert C Smith +14 more
doaj +1 more source
Evaluating Treatment Mechanisms of Varenicline: Mediation by Affect and Craving.
Nicotine & Tobacco Research, 2022 INTRODUCTION Negative reinforcement models posit that relapse to cigarette smoking is driven in part by changes in affect and craving during the quit attempt.
S. Tonkin +8 more
semanticscholar +1 more source
BMJ Open, 2019 Objectives Our primary objective was to estimate smoking prevalence and prescribing rates of varenicline and nicotine replacement therapy (NRT) in people with and without general practitioner (GP)-recorded dementia.
Amy Taylor +6 more
doaj +1 more source
Varenicline Interactions at the 5-HT3 Receptor Ligand Binding Site are Revealed by 5-HTBP. [PDF]
, 2015 Cys-loop receptors are the site of action of many therapeutic drugs. One of these is the smoking cessation agent varenicline, which has its major therapeutic effects at nicotinic acetylcholine (nACh) receptors but also acts at 5-HT3 receptors.
Lillestol, Reidun K +3 more
core +3 more sources
Frontiers in Pharmacology, 2022 This study aimed to build a nasal semi-physiologically based pharmacokinetic (PBPK) model to predict the intranasal pharmacokinetic (PK) of the OC-01(varenicline) nasal spray and accelerate the development of this drug.
Xiaofei Wu +8 more
semanticscholar +1 more source
Use of varenicline for smoking cessation treatment in UK primary care: an association rule mining analysis [PDF]
, 2014 BACKGROUND: Varenicline is probably the most effective smoking cessation pharmacotherapy, but is less widely used than nicotine replacement therapy. We therefore set out to identify the characteristics of numerically important groups of patients who ...
Action on Smoking and Health (ASH) +24 more
core +3 more sources
Ophthalmology and Therapy, 2022 Introduction This study sought to compare the efficacy of OC-01 (varenicline solution) nasal spray for treatment of dry eye disease (DED) in postmenopausal women (PM+) versus women who were not postmenopausal (PM−).
Lisa M. Nijm +6 more
semanticscholar +1 more source